Metabolomic and omic assessment of biological ageing across the life-course (METAGE)
生命全程生物衰老的代谢组学和组学评估 (METAGE)
基本信息
- 批准号:MR/Y02012X/1
- 负责人:
- 金额:$ 75.69万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Fellowship
- 财政年份:2024
- 资助国家:英国
- 起止时间:2024 至 无数据
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Both genetic and environmental factors affect the ageing process, leading to differences in ageing rates. Therefore, a person's "biological age", or overall physiological state, may differ from what is expected given their actual (chronological) age. Differences in biological aging rates mean some people die earlier and have more health problems in later life. In the first part of my project, I used metabolomics (whole sets of metabolites or small molecules) data from multiple population-based cohort studies in the UK, Europe, and the USA, to develop blood tests of biological age using advanced statistics. We found that the metabolomic-based biological age tests provided improved prediction, over chronological age itself, of age-related ill health and mortality. Furthermore, We found that that biological ageing was slower over two years among people who were supported to follow a healthier lifestyle, compared to those who did not receive this support in the FINGER study. For the next part of my project, I will examine if the metabolomic-based biological age test can predict cognitive and physical aging among two cohort studies of older people (the CHARIOT PRO and TILDA studies). I will further refine the metabolomic-based biological age test, so it is less expensive and easier to measure in clinical laboratories. I will also test the use of proteins, another biologically important class of molecules, to develop biological age models in over 20,000 people in the EPIC and CHARIOT PRO studies. Since we know which organs in the body produce specific proteins, it is possible to test "organ-specific" ageing. This is useful as different biological systems in the body may age at different rates, and I will test organ-specific ageing against many types of disease. Furthermore, I will use genetic data and a technique called Medelian Randomization to test if proteins and metabolites that are correlated with age, may cause unhealthy ageing. I will use this information to further improve the biological age tests. Finally, I will analysis the pathways that connect proteins, metabolites and genetic factors involved in ageing to more deeply understand the biological processes that change with age.
遗传和环境因素都会影响衰老过程,导致衰老速度存在差异。因此,一个人的“生物年龄”或整体生理状态可能与其实际(按时间顺序)年龄的预期不同。生物衰老率的差异意味着有些人会更早死亡,并且在晚年会出现更多的健康问题。在我的项目的第一部分中,我使用来自英国、欧洲和美国多个基于人群的队列研究的代谢组学(整组代谢物或小分子)数据,利用先进的统计数据开发生物年龄的血液测试。我们发现,与实际年龄本身相比,基于代谢组学的生物年龄测试可以更好地预测与年龄相关的健康状况不佳和死亡率。此外,我们发现,在 FINGER 研究中,与未接受更健康生活方式支持的人相比,在两年内获得支持的人的生物衰老速度较慢。在我的项目的下一部分中,我将研究基于代谢组学的生物年龄测试是否可以在两项针对老年人的队列研究(CHARIOT PRO 和 TILDA 研究)中预测认知和身体衰老。我将进一步完善基于代谢组学的生物年龄测试,使其更便宜且更容易在临床实验室中测量。我还将在 EPIC 和 CHIOT PRO 研究中测试使用蛋白质(另一类生物学上重要的分子)来为 20,000 多人开发生物年龄模型。由于我们知道体内的哪些器官产生特定蛋白质,因此可以测试“器官特异性”衰老。这很有用,因为体内不同的生物系统可能以不同的速度老化,我将针对多种类型的疾病测试器官特异性老化。此外,我将使用遗传数据和一种称为麦德尔随机化的技术来测试与年龄相关的蛋白质和代谢物是否可能导致不健康的衰老。我将利用这些信息进一步改进生物年龄测试。最后,我将分析与衰老相关的蛋白质、代谢物和遗传因素之间的联系途径,以更深入地了解随年龄变化的生物过程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Oliver Robinson其他文献
242. Translational Computational Assessment of Approach-Avoidance Conflict in Human Anxiety
- DOI:
10.1016/j.biopsych.2023.02.482 - 发表时间:
2023-05-01 - 期刊:
- 影响因子:
- 作者:
Yumeya Yamamori;Jonathan Roiser;Oliver Robinson - 通讯作者:
Oliver Robinson
COVID-19 Lockdown Policies: An Interdisciplinary Review
COVID-19 封锁政策:跨学科审查
- DOI:
10.2139/ssrn.3782395 - 发表时间:
2021 - 期刊:
- 影响因子:0
- 作者:
Oliver Robinson - 通讯作者:
Oliver Robinson
Navigating Groundlessness: An interview study on dealing with ontological shock and existential distress following psychedelic experiences
导航无根据:关于处理迷幻经历后本体冲击和存在困扰的访谈研究
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
E. K. Argyri;Jules Evans;David Luke;Pascal Michael;Katrina Michelle;Cyrus Rohani;Shayam Suseelan;Ed Prideaux;Rosalind McAlpine;Ashleigh Murphy;Oliver Robinson - 通讯作者:
Oliver Robinson
870. Induced Anxiety Leads to Underestimating Time
- DOI:
10.1016/j.biopsych.2017.02.595 - 发表时间:
2017-05-15 - 期刊:
- 影响因子:
- 作者:
Ioannis Sarigiannidis;Monique Ernst;Christian Grillon;Jonathan Roiser;Oliver Robinson - 通讯作者:
Oliver Robinson
Association of environmental noise exposure with cortisol levels in children from eight European birth cohorts
来自八个欧洲出生队列的儿童环境噪声暴露与皮质醇水平的关联
- DOI:
10.1016/j.envres.2025.121541 - 发表时间:
2025-07-15 - 期刊:
- 影响因子:7.700
- 作者:
Ane Arregi;Oliver Robinson;Gunn Marit Aasvang;Sandra Andrusaityte;Audrius Dedele;Jorunn Evandt;Gonzalo Garcia-Baquero;Norun Hjertager Krog;Mònica Guxens;Vincent W.V. Jaddoe;Marianna Karachaliou;Aitana Lertxundi;Katerina Margetaki;Rosemary McEachan;Mark Nieuwenhuijsen;Claire Philippat;Oscar J. Pozo;Remy Slama;Mikel Subiza-Pérez;Elisabeth F.C. van Rossum;Nerea Lertxundi - 通讯作者:
Nerea Lertxundi
Oliver Robinson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Oliver Robinson', 18)}}的其他基金
Metabolomic and omic assessment of biological ageing across the life-course (METAGE)
生命全程生物衰老的代谢组学和组学评估 (METAGE)
- 批准号:
MR/S03532X/1 - 财政年份:2020
- 资助金额:
$ 75.69万 - 项目类别:
Fellowship
MICA: The Translational, Computational and Neurocognitive Basis of Anxiety
MICA:焦虑的转化、计算和神经认知基础
- 批准号:
MR/R020817/1 - 财政年份:2018
- 资助金额:
$ 75.69万 - 项目类别:
Fellowship
TUNING THE NEURAL CIRCUITRY OF AFFECTIVE BIASES IN DEPRESSION
调整抑郁症中情感偏差的神经回路
- 批准号:
MR/K024280/1 - 财政年份:2013
- 资助金额:
$ 75.69万 - 项目类别:
Fellowship
相似海外基金
Proteomic and integrative omic profiles of sugar- and artificially sweetened beverage consumption and changes in type 2 diabetes risk factors
糖和人工甜味剂饮料消费的蛋白质组学和综合组学特征以及 2 型糖尿病危险因素的变化
- 批准号:
10723200 - 财政年份:2023
- 资助金额:
$ 75.69万 - 项目类别:
Integrative multi-omic risk assessment at diagnosis and during disease progression in African-Americans with Inflammatory bowel disease
非洲裔美国人炎症性肠病诊断和疾病进展期间的综合多组学风险评估
- 批准号:
10707294 - 财政年份:2022
- 资助金额:
$ 75.69万 - 项目类别:
Integrative multi-omic risk assessment at diagnosis and during disease progression in African-Americans with Inflammatory bowel disease
非洲裔美国人炎症性肠病诊断和疾病进展期间的综合多组学风险评估
- 批准号:
10543004 - 财政年份:2022
- 资助金额:
$ 75.69万 - 项目类别:
The Gut Microbiota in Metabolic Surgery: A Multi-Ethnic, Multi-Omic, Longitudinal Study
代谢手术中的肠道微生物群:一项多种族、多组学、纵向研究
- 批准号:
10551244 - 财政年份:2021
- 资助金额:
$ 75.69万 - 项目类别:
The Gut Microbiota in Metabolic Surgery: A Multi-Ethnic, Multi-Omic, Longitudinal Study
代谢手术中的肠道微生物群:一项多种族、多组学、纵向研究
- 批准号:
10093513 - 财政年份:2021
- 资助金额:
$ 75.69万 - 项目类别:
Plaque and blood derived macrophages: a multi-omic assessment of CVD pathogenesis in PLWH
斑块和血液来源的巨噬细胞:PLWH CVD 发病机制的多组学评估
- 批准号:
10275181 - 财政年份:2021
- 资助金额:
$ 75.69万 - 项目类别:
Multi-omic functional assessment of novel AD variants using high-throughput and single-cell technologies
使用高通量和单细胞技术对新型 AD 变体进行多组学功能评估
- 批准号:
10684210 - 财政年份:2021
- 资助金额:
$ 75.69万 - 项目类别:
geneXwell: Multidimensional Omic Risk Models and Dynamic Visualizations to Drive Positive Change in Employee Behavioral Economics
geneXwell:多维组学风险模型和动态可视化推动员工行为经济学的积极变化
- 批准号:
10325942 - 财政年份:2021
- 资助金额:
$ 75.69万 - 项目类别:
The Gut Microbiota in Metabolic Surgery: A Multi-Ethnic, Multi-Omic, Longitudinal Study
代谢手术中的肠道微生物群:一项多种族、多组学、纵向研究
- 批准号:
10341050 - 财政年份:2021
- 资助金额:
$ 75.69万 - 项目类别:
Multi-omic functional assessment of novel AD variants using high-throughput and single-cell technologies
使用高通量和单细胞技术对新型 AD 变体进行多组学功能评估
- 批准号:
10436207 - 财政年份:2021
- 资助金额:
$ 75.69万 - 项目类别: